-
2
-
-
84878523797
-
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model
-
Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, et al. Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. PLoS One. 2013; 8:e65075.
-
(2013)
PLoS One.
, vol.8
, pp. e65075
-
-
Nur, H.1
Fostier, K.2
Aspeslagh, S.3
Renmans, W.4
Bertrand, E.5
Leleu, X.6
Favreau, M.7
Breckpot, K.8
Schots, R.9
De Waele, M.10
Van Valckenborgh, E.11
De Bruyne, E.12
Facon, T.13
-
3
-
-
84929599171
-
The Role of Invariant Natural Killer T Cells in Cancer
-
Nur H, Van Valckenborgh E, De Bruyne E, Vanderkerken K, Menu E. The Role of Invariant Natural Killer T Cells in Cancer. Int Blood Res Rev. 2014; 1:44-71.
-
(2014)
Int Blood Res Rev.
, vol.1
, pp. 44-71
-
-
Nur, H.1
Van Valckenborgh, E.2
De Bruyne, E.3
Vanderkerken, K.4
Menu, E.5
-
4
-
-
84861015140
-
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes
-
Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol. 2012; 2012:196063.
-
(2012)
Clin Dev Immunol.
, vol.2012
, pp. 196063
-
-
Rutella, S.1
Locatelli, F.2
-
5
-
-
84865606568
-
The application and biology of immunomodulatory drugs (IMiDs) in cancer
-
Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther. 2012; 136:56-68.
-
(2012)
Pharmacol Ther.
, vol.136
, pp. 56-68
-
-
Pan, B.1
Lentzsch, S.2
-
6
-
-
0034551670
-
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells
-
Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. American Society of Hematology. 2000; 96:3838-46.
-
(2000)
Blood. American Society of Hematology.
, vol.96
, pp. 3838-3846
-
-
Bronte, V.1
Apolloni, E.2
Cabrelle, A.3
Ronca, R.4
Serafini, P.5
Zamboni, P.6
Restifo, N.P.7
Zanovello, P.8
-
8
-
-
33749425534
-
+ T cells
-
+ T cells. J Clin Invest. 2006; 116:2777-90.
-
(2006)
J Clin Invest.
, vol.116
, pp. 2777-2790
-
-
Gallina, G.1
Dolcetti, L.2
Serafini, P.3
De Santo, C.4
Marigo, I.5
Colombo, M.P.6
Basso, G.7
Brombacher, F.8
Borrello, I.9
Zanovello, P.10
Bicciato, S.11
Bronte, V.12
-
9
-
-
43249130187
-
Identification of discrete tumorinduced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
-
Movahedi K, Guilliams M, Van Den Bossche J, Van Den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumorinduced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008; 111:4233-44.
-
(2008)
Blood.
, vol.111
, pp. 4233-4244
-
-
Movahedi, K.1
Guilliams, M.2
Van Den Bossche, J.3
Van Den Bergh, R.4
Gysemans, C.5
Beschin, A.6
De Baetselier, P.7
Van Ginderachter, J.A.8
-
12
-
-
84856706929
-
Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients
-
Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012; 61:255-63.
-
(2012)
Cancer Immunol Immunother.
, vol.61
, pp. 255-263
-
-
Filipazzi, P.1
Huber, V.2
Rivoltini, L.3
-
13
-
-
77956920766
-
Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells
-
Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. American Association of Immunologists. 2010; 185:2273-84.
-
(2010)
J Immunol. American Association of Immunologists.
, vol.185
, pp. 2273-2284
-
-
Lechner, M.G.1
Liebertz, D.J.2
Epstein, A.L.3
-
14
-
-
84922432522
-
Myeloid derived suppressor cells as therapeutic target in hematological malignancies
-
De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA. Myeloid derived suppressor cells as therapeutic target in hematological malignancies. Hematol Oncol. Frontiers. 2014; 4.
-
(2014)
Hematol Oncol. Frontiers
, pp. 4
-
-
De Veirman, K.1
Van Valckenborgh, E.2
Lahmar, Q.3
Geeraerts, X.4
De Bruyne, E.5
Menu, E.6
Van Riet, I.7
Vanderkerken, K.8
Van Ginderachter, J.A.9
-
15
-
-
78650756969
-
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
-
Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011; 32:19-25.
-
(2011)
Trends Immunol.
, vol.32
, pp. 19-25
-
-
Condamine, T.1
Gabrilovich, D.I.2
-
16
-
-
79953113052
-
Transcription factors in myeloid-derived suppressor cell recruitment and function
-
Sonda N, Chioda M, Zilio S, Simonato F, Bronte V. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol. 2011; 23:279-85.
-
(2011)
Curr Opin Immunol.
, vol.23
, pp. 279-285
-
-
Sonda, N.1
Chioda, M.2
Zilio, S.3
Simonato, F.4
Bronte, V.5
-
17
-
-
27144538568
-
Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway
-
Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005; 65:9525-35.
-
(2005)
Cancer Res.
, vol.65
, pp. 9525-9535
-
-
Nefedova, Y.1
Nagaraj, S.2
Rosenbauer, A.3
Muro-Cacho, C.4
Sebti, S.M.5
Gabrilovich, D.I.6
-
18
-
-
84879452593
-
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
-
Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013; 121:2975-87.
-
(2013)
Blood.
, vol.121
, pp. 2975-2987
-
-
Görgün, G.T.1
Whitehill, G.2
Anderson, J.L.3
Hideshima, T.4
Maguire, C.5
Laubach, J.6
Raje, N.7
Munshi, N.C.8
Richardson, P.G.9
Anderson, K.C.10
-
19
-
-
84875442375
-
Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow
-
Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, Roth J, Gabrilovich D, Nefedova Y. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 2013; 190:3815-23.
-
(2013)
J Immunol.
, vol.190
, pp. 3815-3823
-
-
Ramachandran, I.R.1
Martner, A.2
Pisklakova, A.3
Condamine, T.4
Chase, T.5
Vogl, T.6
Roth, J.7
Gabrilovich, D.8
Nefedova, Y.9
-
20
-
-
84869093412
-
Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow
-
Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, Menu E, De Baetselier P, Vanderkerken K, Van Ginderachter JA. Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia. 2012; 26:2424-8.
-
(2012)
Leukemia.
, vol.26
, pp. 2424-2428
-
-
Van Valckenborgh, E.1
Schouppe, E.2
Movahedi, K.3
De Bruyne, E.4
Menu, E.5
De Baetselier, P.6
Vanderkerken, K.7
Van Ginderachter, J.A.8
-
21
-
-
84929599172
-
Tumor-induced CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients
-
(Dec 30)
-
Wang Z, Zhang L, Wang H, Xiong S, Li Y, Tao Q, Xiao W, Qin H, Wang Y, Zhai Z. Tumor-induced CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Cancer Immunol Immunother. 2014; (Dec 30).
-
(2014)
Cancer Immunol Immunother.
-
-
Wang, Z.1
Zhang, L.2
Wang, H.3
Xiong, S.4
Li, Y.5
Tao, Q.6
Xiao, W.7
Qin, H.8
Wang, Y.9
Zhai, Z.10
-
22
-
-
84866636386
-
The secret of MIM: a novel, MCL-1-specific small molecule
-
Kritzer JA. The secret of MIM: a novel, MCL-1-specific small molecule. Chem Biol. 2012; 19:1082-3.
-
(2012)
Chem Biol.
, vol.19
, pp. 1082-1083
-
-
Kritzer, J.A.1
-
23
-
-
0030749836
-
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse
-
Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I, Thielemans K, Van Camp B. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer. 1997; 76:451-60.
-
(1997)
Br J Cancer.
, vol.76
, pp. 451-460
-
-
Vanderkerken, K.1
De Raeve, H.2
Goes, E.3
Van Meirvenne, S.4
Radl, J.5
Van Riet, I.6
Thielemans, K.7
Van Camp, B.8
-
24
-
-
84869222349
-
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
-
Zhuang J, Zhang J, Lwin ST, Edwards JR, Edwards CM, Mundy GR, Yang X. Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One. 2012; 7:e48871.
-
(2012)
PLoS One.
, vol.7
, pp. e48871
-
-
Zhuang, J.1
Zhang, J.2
Lwin, S.T.3
Edwards, J.R.4
Edwards, C.M.5
Mundy, G.R.6
Yang, X.7
-
25
-
-
84870429906
-
Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice
-
Ma C, Kapanadze T, Gamrekelashvili J, Manns MP, Korangy F, Greten TF. Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012; 92:1199-206.
-
(2012)
J Leukoc Biol.
, vol.92
, pp. 1199-1206
-
-
Ma, C.1
Kapanadze, T.2
Gamrekelashvili, J.3
Manns, M.P.4
Korangy, F.5
Greten, T.F.6
-
26
-
-
38149005534
-
Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice
-
Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol. 2008; 83:64-70.
-
(2008)
J Leukoc Biol.
, vol.83
, pp. 64-70
-
-
Daley, J.M.1
Thomay, A.A.2
Connolly, M.D.3
Reichner, J.S.4
Albina, J.E.5
-
27
-
-
73249125588
-
Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells
-
Ribechini E, Leenen PJM, Lutz MB. Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol. 2009; 39:3538-51.
-
(2009)
Eur J Immunol.
, vol.39
, pp. 3538-3551
-
-
Ribechini, E.1
Leenen, P.J.M.2
Lutz, M.B.3
-
28
-
-
84928583389
-
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation
-
De Keersmaecker B, Fostier K, Corthals J, Wilgenhof S, Heirman C, Aerts JL, Thielemans K, Schots R. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol Immunother. 2014; 63:1023-36.
-
(2014)
Cancer Immunol Immunother.
, vol.63
, pp. 1023-1036
-
-
De Keersmaecker, B.1
Fostier, K.2
Corthals, J.3
Wilgenhof, S.4
Heirman, C.5
Aerts, J.L.6
Thielemans, K.7
Schots, R.8
-
30
-
-
84880948301
-
Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer
-
Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol. 2013; 3:49.
-
(2013)
Front Oncol.
, vol.3
, pp. 49
-
-
Najjar, Y.G.1
Finke, J.H.2
-
31
-
-
84891831968
-
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials
-
Molina AM, Lin X, Korytowsky B, Matczak E, Lechuga MJ, Wiltshire R, Motzer RJ. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer. 2014; 50:351-8.
-
(2014)
Eur J Cancer.
, vol.50
, pp. 351-358
-
-
Molina, A.M.1
Lin, X.2
Korytowsky, B.3
Matczak, E.4
Lechuga, M.J.5
Wiltshire, R.6
Motzer, R.J.7
-
32
-
-
84929578181
-
Administration Of An Oral PDE5 Inhibitor, Tadalafil In Conjunction With a Lenalidomide Containing Regimen In Patients With Multiple Myeloma-The Myeloma Beacon
-
Ash meeting. p. New Orleans
-
N. Ghosh, L. Rudraraju, X. Ye, K. Noonan, C.A. Huff IB. Administration Of An Oral PDE5 Inhibitor, Tadalafil In Conjunction With a Lenalidomide Containing Regimen In Patients With Multiple Myeloma-The Myeloma Beacon. Ash meeting. p. New Orleans.
-
-
-
Ghosh, N.1
Rudraraju, L.2
Ye, X.3
Noonan, K.4
Huff, C.A.I.B.5
-
33
-
-
84910071057
-
Targeting immune suppression with PDE5 inhibition in endstage multiple myeloma
-
Noonan KA, Ghosh N, Rudraraju L, Bui M, Borrello I. Targeting immune suppression with PDE5 inhibition in endstage multiple myeloma. Cancer Immunol Res. American Association for Cancer Research. 2014; 2:725-31.
-
(2014)
Cancer Immunol Res. American Association for Cancer Research.
, vol.2
, pp. 725-731
-
-
Noonan, K.A.1
Ghosh, N.2
Rudraraju, L.3
Bui, M.4
Borrello, I.5
-
34
-
-
84894098516
-
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
-
Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 2014; 63:1769-81.
-
(2014)
Gut.
, vol.63
, pp. 1769-1781
-
-
Stromnes, I.M.1
Brockenbrough, J.S.2
Izeradjene, K.3
Carlson, M.A.4
Cuevas, C.5
Simmons, R.M.6
Greenberg, P.D.7
Hingorani, S.R.8
-
35
-
-
0025633094
-
Granulocyte-macrophage colonystimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells
-
Zhang X, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B. Granulocyte-macrophage colonystimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood. 1990; 76:2599-605.
-
(1990)
Blood.
, vol.76
, pp. 2599-2605
-
-
Zhang, X.1
Bataille, R.2
Jourdan, M.3
Saeland, S.4
Banchereau, J.5
Mannoni, P.6
Klein, B.7
-
36
-
-
77956920766
-
Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells
-
Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010; 185:2273-84.
-
(2010)
J Immunol.
, vol.185
, pp. 2273-2284
-
-
Lechner, M.G.1
Liebertz, D.J.2
Epstein, A.L.3
-
37
-
-
84903957798
-
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients
-
Busch A, Zeh D, Janzen V, Mügge L-O, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol. 2014; 177:439-53.
-
(2014)
Clin Exp Immunol.
, vol.177
, pp. 439-453
-
-
Busch, A.1
Zeh, D.2
Janzen, V.3
Mügge, L.-O.4
Wolf, D.5
Fingerhut, L.6
Hahn-Ast, C.7
Maurer, O.8
Brossart, P.9
von Lilienfeld-Toal, M.10
-
38
-
-
0037305848
-
Loss of S100A9 (MRP14) Results in Reduced Interleukin-8-Induced CD11b Surface Expression, a Polarized Microfilament System, and Diminished Responsiveness to Chemoattractants In Vitro
-
Manitz M-P, Horst B, Seeliger S, Strey A, Skryabin B V., Gunzer M, Frings W, Schonlau F, Roth J, Sorg C, Nacken W. Loss of S100A9 (MRP14) Results in Reduced Interleukin-8-Induced CD11b Surface Expression, a Polarized Microfilament System, and Diminished Responsiveness to Chemoattractants In Vitro. Mol Cell Biol. 2003; 23:1034-43.
-
(2003)
Mol Cell Biol.
, vol.23
, pp. 1034-1043
-
-
Manitz, M.-P.1
Horst, B.2
Seeliger, S.3
Strey, A.4
Skryabin, B.V.5
Gunzer, M.6
Frings, W.7
Schonlau, F.8
Roth, J.9
Sorg, C.10
Nacken, W.11
-
39
-
-
0033605359
-
Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophil. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase
-
Al-Shami A, Naccache PH. Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophil. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase. J Biol Chem. 1999; 274:5333-8.
-
(1999)
J Biol Chem.
, vol.274
, pp. 5333-5338
-
-
Al-Shami, A.1
Naccache, P.H.2
-
40
-
-
84875866083
-
STAT3 regulates arginase-I in myeloidderived suppressor cells from cancer patients
-
Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang H, Pardoll D, Kim Y. STAT3 regulates arginase-I in myeloidderived suppressor cells from cancer patients. J Clin Invest. 2013; 123:1580-9.
-
(2013)
J Clin Invest.
, vol.123
, pp. 1580-1589
-
-
Vasquez-Dunddel, D.1
Pan, F.2
Zeng, Q.3
Gorbounov, M.4
Albesiano, E.5
Fu, J.6
Blosser, R.L.7
Tam, A.J.8
Bruno, T.9
Zhang, H.10
Pardoll, D.11
Kim, Y.12
-
41
-
-
84866654914
-
A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival
-
Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, Opferman JT, Walensky LD. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol. Elsevier. 2012; 19:1175-86.
-
(2012)
Chem Biol. Elsevier.
, vol.19
, pp. 1175-1186
-
-
Cohen, N.A.1
Stewart, M.L.2
Gavathiotis, E.3
Tepper, J.L.4
Bruekner, S.R.5
Koss, B.6
Opferman, J.T.7
Walensky, L.D.8
-
42
-
-
84918555897
-
Myeloid-Derived Suppressor Activity Is Mediated by Monocytic Lineages Maintained by Continuous Inhibition of Extrinsic and Intrinsic Death Pathways
-
Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ. Myeloid-Derived Suppressor Activity Is Mediated by Monocytic Lineages Maintained by Continuous Inhibition of Extrinsic and Intrinsic Death Pathways. Immunity. Elsevier. 2014; 41:947-59.
-
(2014)
Immunity. Elsevier.
, vol.41
, pp. 947-959
-
-
Haverkamp, J.M.1
Smith, A.M.2
Weinlich, R.3
Dillon, C.P.4
Qualls, J.E.5
Neale, G.6
Koss, B.7
Kim, Y.8
Bronte, V.9
Herold, M.J.10
Green, D.R.11
Opferman, J.T.12
Murray, P.J.13
-
43
-
-
84883162955
-
+ regulatory T cells
-
+ regulatory T cells. Nat Immunol. 2013; 14:959-65.
-
(2013)
Nat Immunol.
, vol.14
, pp. 959-965
-
-
Pierson, W.1
Cauwe, B.2
Policheni, A.3
Schlenner, S.M.4
Franckaert, D.5
Berges, J.6
Humblet-Baron, S.7
Schönefeldt, S.8
Herold, M.J.9
Hildeman, D.10
Strasser, A.11
Bouillet, P.12
Lu, L.-F.13
-
44
-
-
0036659905
-
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells
-
Derenne S. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood. 2002; 100:194-9.
-
(2002)
Blood.
, vol.100
, pp. 194-199
-
-
Derenne, S.1
-
45
-
-
0034584607
-
The 5TMM series: a useful in vivo mouse model of human multiple myeloma
-
Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K. The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J. 2000; 1:351-6.
-
(2000)
Hematol J.
, vol.1
, pp. 351-356
-
-
Asosingh, K.1
Radl, J.2
Van Riet, I.3
Van Camp, B.4
Vanderkerken, K.5
-
46
-
-
34250749795
-
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging
-
Oyajobi BO, Muñoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther. 2007; 6:1701-8.
-
(2007)
Mol Cancer Ther.
, vol.6
, pp. 1701-1708
-
-
Oyajobi, B.O.1
Muñoz, S.2
Kakonen, R.3
Williams, P.J.4
Gupta, A.5
Wideman, C.L.6
Story, B.7
Grubbs, B.8
Armstrong, A.9
Dougall, W.C.10
Garrett, I.R.11
Mundy, G.R.12
-
47
-
-
77950556094
-
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms
-
De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010; 115:2430-40.
-
(2010)
Blood.
, vol.115
, pp. 2430-2440
-
-
De Bruyne, E.1
Bos, T.J.2
Schuit, F.3
Van Valckenborgh, E.4
Menu, E.5
Thorrez, L.6
Atadja, P.7
Jernberg-Wiklund, H.8
Vanderkerken, K.9
|